Lack of sister chromatid exchange induction in phenytoin-treated patients with epilepsy.
Phenytoin (PHT) has been suspected of having a mutagenic effect with chronic administration, but the existing evidence is equivocal. Contradictory results have been obtained using different testing systems. Sister chromatid exchange (SCE), a sensitive indicator of genotoxic environmental influences, has been used in only a few limited studies of PHT users, with varying results. The present study was designed to evaluate the potential mutagenicity of PHT in a more objective and reliable way than has been done previously. Following careful screening procedures, 16 adult male patients with epilepsy receiving long-term PHT monotherapy and 16 healthy controls were selected for a study of SCE frequencies in peripheral lymphocytes. The patients and controls were matched for sex, age, and smoking habits. Strict exclusionary criteria were observed, including all factors known to affect or suspected of affecting the SCE frequencies. Statistical analyses did not reveal any significant differences between the SCE rates of PHT-treated patients and controls, indicating a lack of PHT mutagenicity as expressed by induction of SCE in adults.
Schaumann
B A
BA
Research Service, VA Medical Center, Minneapolis, MN 55147.
Winge
V B
VB
Garry
V F
VF
D000328:Adult; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009153:Mutagens; D010672:Phenytoin / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D012854:Sister Chromatid Exchange / Q000187:drug effects*; D012907:Smoking / Q000097:blood
D009153:Mutagens; D010672:Phenytoin